Lasergen

What Lasergen does

Lasergen is a privately held biotechnology company founded in 2002 and headquartered in Houston, Texas. Per firmographic data, the company develops and commercializes technologies for genomic applications, operating with a small team of 11-50 employees. Specific product details, technical platforms, pipeline assets, and commercial offerings are not disclosed in the available source material, leaving the underlying scientific or technological approach undefined beyond the general genomics category.

The company has raised a cumulative $85 million across two disclosed funding rounds. The first, a $5 million Series 2 in August 2011, was led by Aspen MedTech with participation from LBS Technologies. The second, a substantially larger $80 million Series 2 in March 2016, was led by Agilent Technologies — a major publicly traded life-sciences analytical instruments company (NYSE: A) with global reach across 110 countries. The Agilent investment represents the most significant signal in the dataset, both as a capital event and as a potential strategic alignment with a major life-sciences tools distributor, though no commercial agreement, co-development arrangement, or distribution partnership is documented in the source.

No management team, board composition, partnerships beyond investors, regulatory milestones, M&A activity, product launches, or revenue figures are present in the source material. As a result, the company's current operational status, commercial maturity, and growth direction cannot be assessed from the available evidence. The investment thesis around Lasergen is therefore constrained to its genomics focus, its small operating footprint, and its strategic investor base.

Name

Lasergen

Legal name

Agilent Technologies, Inc.

Website

https://lasergen.com

Company type

Public

Founded year

2002

Operating status

Operating

Headcount range

11–50 employees

Short description

Lasergen is a privately held Houston-based biotechnology company founded in 2002 that develops technologies for genomic applications, operating with 11-50 employees and having raised $85M across two funding rounds led by Agilent Technologies and Aspen MedTech.

Ownership category

akta.pro rank

Product category

Genomics Biotechnology

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

akta.pro secondary industry

Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

Keywords

• Genomic technologies
• Biotechnology research
• Genomics applications
• Life sciences tools
• Molecular biology

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Laboratory Instruments and Systems: Sale of analytical instruments including liquid chromatography, gas chromatography, mass spectrometry, atomic spectroscopy, and cell analysis systems. Revenue generated through direct sales, enterprise contracts, and product transactions.
2. Supplies and Consumables: Recurring revenue from consumables including HPLC columns, PFAS testing kits, and other laboratory supplies required for instrument operation.
3. Software and Informatics: Licensing and maintenance of software solutions including OpenLab CDS chromatography data systems and other informatics platforms.
4. CrossLab Services and Support: Maintenance, repair, service plans, and support services for laboratory instruments. Includes software upgrades support and service agreements.
5. Specialty CDMO Services: Contract development and manufacturing organization services for biopharmaceutical applications.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Lasergen is a biotechnology company that develops and commercializes technologies for genomic applications. The company focuses on genomic technology R&D aimed at enabling life-sciences and biotechnology customers to apply genomic methods in research and commercial settings.

Differentiator

Problem solved

Functional benefit

Brands

• CrossLab: Laboratory services and support division offering instrument services, maintenance, and digital services
• OpenLab CDS
• Agilent Foundation

Segments6 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

One partnership is on record.

• Biocare MedicalcoreStrategic or Co-development PartnerBiocare Medical has been acquired by Agilent and is now part of Agilent's pathology solutions portfolio. The acquisition advances pathology innovations and solutions, combining Biocare's staining and immunohistochemistry expertise with Agilent's broader analytical and diagnostic capabilities.

Scale indicators2 records

Recent moves2 records

Expansion highlights2 records

Direct peers

• Pacific Biosciences: Developer of long-read DNA sequencing platforms (SMRT technology) for genomic applications. Comparable to Lasergen as a focused genomic-technology vendor building differentiated instrumentation for sequencing and molecular analysis.
• NanoString Technologies: Genomics technology company offering spatial transcriptomics and gene-expression profiling platforms. Comparable to Lasergen as a focused genomic-instrumentation vendor serving translational and clinical research customers.
• 10x Genomics: Genomics technology company developing instruments and consumables for single-cell, spatial, and exome analysis. Closely comparable to Lasergen's genomic-application focus, addressing similar research and translational customers with platform-based solutions.
• QIAGEN: Provider of sample-preparation and molecular diagnostics technologies widely used in genomic workflows. Comparable to Lasergen as a molecular/genomic-tools vendor serving research and clinical customers with enabling technologies.
• Standard BioTools (Fluidigm): Developer of mass cytometry and single-cell genomics instrumentation. Comparable to Lasergen as a smaller, technology-focused vendor building genomic and molecular-analysis platforms for research applications.
• Illumina: Dominant DNA sequencing and genomics technology provider offering instruments, reagents, and analysis tools. Directly comparable to Lasergen as a genomics-technology platform serving research and clinical applications, though operating at vastly greater scale.

Broad incumbents

• PerkinElmer: Diversified life-sciences and diagnostics company with genomic-analysis and screening products. Comparable as a broader incumbent operating in adjacent genomic-technology categories.
• Thermo Fisher Scientific: Largest life-sciences tools company with broad genomics, sequencing, and molecular-diagnostics portfolio. Comparable as a major incumbent competing for the same genomic-technology customers that Lasergen targets.
• Agilent Technologies: Large life-sciences analytical instrumentation and genomics company; Lasergen's strategic lead investor. Comparable as the genomics-instrumentation incumbent in whose ecosystem Lasergen's technologies are positioned, though operating at vastly greater scale and breadth.
• Bio-Rad Laboratories: Life-sciences and clinical diagnostics company with genomics-adjacent product lines including digital PCR. Comparable as a broad incumbent with overlapping capabilities in genomic analysis technologies.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/lasergen

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lasergen